Coordination of Industrial Biotechnology Activities in the UK S'M' Roberts Oxyrane Ltd and Mancheste

1
Coordination of Industrial Biotechnology
Activities in the UKS.M. Roberts (Oxyrane Ltd
and Manchester University)Cardiff, 12 March 2008
2

• Animals
• Plants
• Fungi
• Bacteria

Baking Brewing Medicines
Gene
cells
3

• Animals
• Plants
• Fungi
• Bacteria

Baking Brewing Medicines
Gene Protein
cells
4
Biopharmaceuticals
Protein Protein Protein
Protein
GM
Food, Feed
Protein
Washing Powders
Enzymes
INDUSTRIAL (WHITE) BIOTECHNOLOGY
Biofuels
Fine Chemicals
5

Cheap (non-natural) materials
Smart chemistry (biocatalysis)
Enzyme
High-value products including pharmaceutical
intermediates
6
The Organisations

• Centre of Excellence in Biocatalysis,
  Biotransformations and Biocatalytic Manufacturing
  (CoEBio3)
• National Industrial Biotechnology Facility (NIBF)
• Oxyrane Ltd

7
CoEBio3 Key ConceptsA Unique Global Enterprise

• Research Centre based in new 38M Manchester
  Interdisciplinary Biocentre (MIB) (www.mib.ac.uk)
  opened January 2006
• Satellite groups at Universities of York,
  Strathclyde and Heriot-Watt providing
  complementary expertise
• Industrial Consortium
• Scale-up facility (NIBF) at Centre for Process
  Innovation (CPI) in Wilton (www.uk-cpi.com)

8
Manchester Interdisciplinary Biocentre
9
National Industrial Biotechnology Facility

• 3.1m project that interfaces with research
  facilities at CoEBio3 developing new
  manufacturing routes using biocatalysts (Genes
  to Kilos)
• Located at Centre for Process Innovation, Wilton
  (www.uk-cpi.com)
• 2 x 1000L fermenters 50L seed tank
• Downstream processing and pre-treatment (novel
  reactor technology, separation capability)
• Opened 1Q 07 fully commissioned
• CoEBio3-CPI offers unique combination

10
Fermentors and Seed Tank NIBF
11
(No Transcript)
12
CoEBio3 Industrial Affiliates
Phase I 2005-2008 (3 years) Almac Lonza
AstraZeneca Merck BASF Novacta Bioniqs
Oxyrane Codexis Pharma Solutions Pfizer DSM
Plymouth Marine Labs DowPharma SAFC Excelsyn
TMO Renewables Ingenza Fees per
annum 40K large 20K medium 5K
small Currently ca. 350K p.a. funds are used
to support PhD students and strategic research
projects
13
CoEBio3 Other Industrial Partnerships

• Income from one-to-one (private) CoEBio3/Company
  (Affiliates and Non-Affiliates) collaborations,
  2M in the first 1½ years

14
Technology Platforms

• Overall Aim
• Exploitation of biocatalysis/biotransformations
  for cost-effective conversion of simple
  feedstocks and substrates into high value
  speciality chemicals.
• This includes pharmaceutical, agrichemical,
  flavour and fragrance ingredients, organic
  materials, biofuels etc.
• Technology Platforms
• Enzyme discovery (cloning, expression,
  screening, evolution)
• Biocatalyst development (formulation,
  immobilisation)
• Process optimisation (novel reactors, solvents)

15
Oxyrane

• Example of a Company using the
• CoEBio3/NIBF Facilities
• Fermentation
• Novel Expression System
• Therapeutic Enzymes
• Cell Surface Displays
• mAbs and Vaccines

16
Oxyrane Commercial Focus
Expression system engineering

• Development of merchant products focused on
  opportunities where
• Current commercial solutions are expensive and/or
  complex
• Product development is applicable to several
  attractive targets
• Technology enables significant cost/performance
  benefits

Chiral bi-functional intermediates
Proteins with post-translational modification

• Therapeutic proteins
• Vaccines

• Pharmaceutical intermediates

17
Oxyrane web-based approach
novel application development
select novel drugs
non-pharma applications

• Opportunity identification
• Technical coordination/integration
• Business development

host pathway engineering (Belgium)
fermentation
expression platform/tools (France)
large-scale chemical synthesis
technology tool development
outsourced production
18
Industrial Biotechnology -Biofuels

• A recent report (www.rabobankgroep.nl) suggests
  biodiesel production will treble in the period
  2005-2010. Biethanol production is expected to
  double in this period.
• The new production units will continue to use
  agricultural crops as feedstock.
  Second-generation technologies are expected to
  kick-in after 2010.
• (paul.goddard_at_manchester.ac.uk)

19
The Future

• Continue to develop cost-effective and
  sustainable solutions for the fine chemical
  manufacture across a range of industries. (Expand
  the number of Affiliate Companies)
• Being the leading UK training organisation for
  white biotechnologists (including bespoke
  re-training courses)
• Use existing expertise and infra-structure
  rapidly to expand into complementary fields. (For
  example, Biofuels and/or Biopharmaceuticals)
• Expand influence in a geographical sense, to
  interact with Companies and key Academic Groups
  in the US, Asia and the Antipodes

20
The Future Funding Going Forward

• May 2008 1.5M over 3 years needed to maintain
  infra-structure (same level as 2005-8)
• Income from Industry to rise to 0.5M p.a. from
  Fees. Income from one-to-one Partnerships to
  grow to at least 2M p.a.
• Self-sustaining 2011 onwards
• Spin-outs anticipated 2008-9

21
Another Dimension
INDUSTRY

CoEBio3
NBC
NBC
NIBF
INDUSTRY
NBC National Biomanufacturing Centre (Speke)
22
Opportunity 1
CoEBioPharm

INDUSTRY
CoEBio3
NBC
NBC
NIBF
CoEBioPharm Proposed Centre of Excellence for
BioPharmaceutical Research
23
Opportunity 2
Bio Fuel Initiative (pan-European)

INDUSTRY
Large Scale Manufacture
CoEBio3
NBC
NIBF